SLC5A2 and hydrops fetalis: In comparison, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) have demonstrated robust benefits in both HFrEF and HFpEF populations, including reductions in mortality and HF hospitalizations across a broad spectrum of patients regardless of diabetes status.